Passage BIO, Inc. — Director's Dealing 2022

Nov 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2022-11-10

Reporting Person: Forman Mark S (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-10	Restricted Stock Unit	$	A	50000	Acquired		Common Stock (50000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.